During Friday’s current trade, PulteGroup, Inc (NYSE:PHM)’s shares gained 2.12%, to $20.00.
PulteGroup, Inc (PHM), will present at the J.P. Morgan Homebuilding & Building Products Conference on Tuesday, May 19, 2015, at 9:20 a.m. (ET).
Interested investors can access the webcast of PulteGroup’s presentation by logging on to the Company’s website at www.pultegroupinc.com and selecting the webcast banner on the home page. Participants are encouraged to log on at least five minutes preceding to the start of the presentation.
PulteGroup, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land. It offers various home designs, counting single-family detached, townhouses, condominiums, and duplexes under the Pulte Homes, Del Webb, and Centex brand names.
NetApp Inc (NASDAQ:NTAP)’s shares dropped -1.17% to $35.54, during the current trading session Friday’s.
After market close on Wednesday, May 20, 2015, NetApp (NASDAQ: NTAP) will declare financial results for the fourth quarter and fiscal year 2015, which ended April 24, 2015.
NetApp executive administration will host a conference call at 2:00 p.m. Pacific Time to talk about these results and provide their perspective on market dynamics. The call will be broadcast live via the Internet.
NetApp Future Targeted Release Dates
Q1 FY 2016 results target date: August 19, 2015
Q2 FY 2016 results target date: November 18, 2015
Q3 FY 2016 results target date: February 17, 2016
Q4 FY 2016 results target date: May 24, 2016
NetApp, Inc. is engaged in design, manufacture, and marketing of networked storage solutions. The company provides storage and data administration software, systems, and services. It offers Data ONTAP storage operating system that delivers integrated data protection, comprehensive data administration, and built-in efficiency software for virtualized, shared infrastructures, cloud computing, and mixed workload business applications; storage efficiency technologies; FlexArray storage virtualization software, which unifies and simplifies IT operations by virtualizing arrays; data protection software products; and data retention and archive products.
In an afternoon trade, Arbor Realty Trust Inc (NYSE:ABR)’s shares climbed 1.20%, to $6.75.
Arbor Realty Trust Inc (ABR), declared financial results for the first quarter ended March 31, 2015. Arbor stated net income for the quarter of $15.0 million, or $0.30 per diluted common share, contrast to $5.9 million, or $0.12 per diluted common share for the quarter ended March 31, 2014. Adjusted funds from operations (“AFFO”) for the quarter was $18.2 million, or $0.36 per diluted common share, contrast to $7.9 million, or $0.16 per diluted common share for the quarter ended March 31, 2014.
At March 31, 2015, the loan and investment portfolio’s unpaid principal balance, not taking into account loan loss reserves, was about $1.75 billion, with a weighted average current interest pay rate of 5.47%, contrast to $1.60 billion and 5.44% at December 31, 2014. Counting certain fees earned and costs associated with the loan and investment portfolio, the weighted average current interest pay rate was 6.07% at March 31, 2015, contrast to 6.16% at December 31, 2014.
The average balance of the Company’s loan and investment portfolio during the first quarter of 2015 and fourth quarter of 2014, not taking into account loan loss reserves, was $1.64 billion. The average yield on these assets for the quarter was 6.71%, contrast to 6.43% for the fourth quarter of 2014. The enhance in average yield was primarily due to an enhance in income from the acceleration of fees on early loan payoffs in the first quarter as contrast to the fourth quarter.
At March 31, 2015, the Company’s total loan loss reserves were $116.5 million regarding10 loans with an aggregate carrying value before loan loss reserves of $222.4 million. The Company also had three non-performing loans with a carrying value of $6.5 million, net of related loan loss reserves of $34.5 million.
During the first quarter, the Company attained a $116.0 million defaulted first mortgage and closed on an $87.0 million warehouse repurchase facility to finance this acquisition. The mortgage and related financing were repaid in full in April 2015. As a result, the Company anticipates to recognize income of about $6.5 million in the second quarter of 2015.
Arbor Realty Trust, Inc., a specialized real estate finance company, invests in various structured finance investments. The company invests in multifamily and commercial real estate-related bridge and mezzanine loans, counting junior participating interests in first mortgages, preferred and direct equity, and discounted mortgage notes and other real estate-related assets. It offers bridge financing products to borrowers who seek short-term capital to be used in an acquisition of property; mezzanine financing in the form of loans that are subordinate to a conventional first mortgage loan and senior to the borrower’s equity in a transaction; junior participation financing in the form of a junior participating interest in the senior debt; and financing by making preferred equity investments in entities that directly or indirectly own real property.
Clovis Oncology Inc (NASDAQ:CLVS), during its Friday’s current trading session dwindled -8.15% to $92.14.
Clovis Oncology Inc (CLVS), declared that two oral presentations and six poster sessions highlighting updated results and trial designs from clinical studies of the company’s three compounds in advanced clinical development are being presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29-June 2, 2015 in Chicago.
“Our data at ASCO this year comprise an update from our TIGER-X study of rociletinib in EGFR-mutated non-small cell lung cancer, which together with data from TIGER-2, will serve as the basis of our intended rolling NDA submission to commence next month, in addition to the first look at the full population of ovarian cancer patients in part one of the ARIEL2 study of rucaparib, which will contribute to our planned 2016 NDA submission,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “We are happy that these data were selected for oral presentations at ASCO this year, and that the FDA has recognized the compelling results observed for both of these compounds by granting Breakthrough Therapy designation for each in the past twelve months.”
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which comprise Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
